Pathogenesis and Treatment in IgA Nephropathy

Part I. Pathogenesis

1. Is IgA Nephropathy a Single Disease?
Chee Kay Cheung, Jonathan Barratt

2. Advances in Genetics of Immunoglobulin A Nephropathy
Hong Zhang, Riccardo Magistroni, Ali Gharavi

3. Is IgA Nephropathy (IgAN) a Familial or Sporadic Disease?
Ichiei Narita, Yoshikatsu Kaneko, Yumi Itoh, Yuichi Sakamaki, Seitaro Iguchi, Suguru Yamamoto, Minako Wakasugi, Junichiro J. Kazama, Shin Goto

4. Heterogeneity of Aberrant O-Glycosylation of IgA1 in IgA Nephropathy
Jan Novak, Kazuo Takahashi, Hitoshi Suzuki, Colin Reily, Tyler Stewart, Hiroyuki Ueda, Koshi Yamada, Zina Moldoveanu, M. Colleen Hastings, Robert J. Wyatt, Jiri Mestecky, Milan Raska, Bruce A. Julian, Matthew B. Renfrow

5. Differences of Histological Classification Between the Japanese Histological Grade Classification and the Oxford Classification
Kensuke Joh, Keely May McNamara

6. Podocyte Injury and Significance of Urinary Podocalyxin and Megalin
Katsuhiko Asanuma

7. Complement Activation
Isao Ohsawa

Part II. Treatment

8. How Different Are the Current Understandings of Treatments for IgA Nephropathy?
Hitoshi Suzuki

9. Prognostic Indicators and Treatment of IgA Nephropathy in China
Wei-Bo Le, Zhi-Hong Liu

10. The Differences in Etiology and Treatment of IgA Nephropathy in Korea
Dong-Wan Chae

11. Differences in Etiology and Treatment in Japan
Ritsuko Katafuchi

12. IgA Nephropathy from the VALIGA European Study: Differences in Treatment Approaches Within Europe
Rosanna Coppo

13. Differences in Etiology and Treatment in Scandinavian Countries
Jukka Mustonen, Kati Kaartinen, Jaana Syrjänen, Ilkka Pörsti

14. The Implication of the KDIGO Clinical Practice Guidelines on Management of IgA Nephropathy
Philip Kam-tao Li, Kai Ming Chow

15. Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines
Kazuo Takahashi, Ryohei Yamamoto, Yukio Yuzawa

16. Limitations of RAS Blockade in IgA Nephropathy
Ryohei Yamamoto

17. What Is the Goal for Proteinuria in IgA Nephropathy?
Kyoko Watanabe, Keita Hirano

18. Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients
Yusuke Suzuki, Rosanna Coppo, Yasuhiko Tomino

19. Is Tonsillectomy a Possible Treatment for IgA Nephropathy from Randomized Controlled Trial (RCT)?
Tetsuya Kawamura

20. Validity of the Japanese Clinical Grade Criteria: Results from the Nationwide Retrospective Cohort Study in IgA Nephropathy
Takashi Yasuda, Yoshinari Yasuda, Sachiko Ohde, Osamu Takahashi, Tetsuya Kawamura, Seiichi Matsuo

Nyckelord: Medicine & Public Health, Nephrology, Urology